David Savello
Berater bei Pappas Capital LLC
Profil
Dave joined Pappas Capital in 2002 as a member of our Scientific Advisory Board, becoming a Venture Advisor in 2012.
He regularly provides clinical development guidance to our portfolio companies – including CoLucid Pharmaceuticals, Milestone Pharmaceuticals and Lumena Pharmaceuticals, where he was a member of the board of directors prior to its acquisition by Shire in 2014.
Dave was most recently Senior Vice President of Development Operations for Xenoport.
Prior to Xenoport, he co-founded NDA Partners, a drug development consulting company.
Prior to NDA Partners, he was Chief Scientific Officer for Cardinal Health, and before that, Senior Vice President for Drug Development at Guilford Pharmaceuticals.
He held senior level positions in drug development and regulatory affairs at Glaxo and Glaxo Wellcome, including Vice President for North American Regulatory Affairs.
Prior to Glaxo, Dave held positions with Warner Lambert Corporation, Boehringer Ingelheim and Riker Laboratories.
Dave served on the North Carolina State University School of Physical and Mathematical Science Foundation Board, and the University of Maryland School of Pharmacy Advisory Committee.
He previously served as a director for Panacos Pharmaceuticals, a Pappas Ventures I portfolio company.
Aktive Positionen von David Savello
| Unternehmen | Position | Beginn |
|---|---|---|
Pappas Capital LLC
 Pappas Capital LLC Investment ManagersFinance Pappas Capital LLC (Pappas Ventures) is a venture capital firm founded in 1994 by Art M. Pappas. The firm is headquartered in Durham, North Carolina. | Berater | 01.01.2002 |
Ehemalige bekannte Positionen von David Savello
| Unternehmen | Position | Ende |
|---|---|---|
| CARDINAL HEALTH, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2005 |
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Corporate Officer/Principal | 01.01.1999 |
| Glaxo, Inc. | Compliance Officer | 01.01.1997 |
| Glaxo Wellcome, Inc. | Compliance Officer | 01.01.1997 |
| University of Maryland School of Pharmacy | Berater | - |
Ausbildung von David Savello
| Massachusetts College of Pharmacy & Health Science | Undergraduate Degree |
| University of Maryland School of Pharmacy | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| CARDINAL HEALTH, INC. | Distribution Services |
| PANACOS PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 9 |
|---|---|
XenoPort, Inc.
 XenoPort, Inc. Pharmaceuticals: MajorHealth Technology XenoPort, Inc. operated as a biopharmaceutical company. Its products included horizant and regnite. The company was founded by Ronald W. Barrett, William J. Dower and Mark A. Gallop on December 17, 1999 and was headquartered in Atlanta, GA. | Health Technology |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
| Glaxo, Inc. | |
| Glaxo Wellcome, Inc. | Health Technology |
Lumena Pharmaceuticals, Inc.
 Lumena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lumena Pharmaceuticals, Inc. developed oral therapeutics for rare liver diseases. The firm was engaged in the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders, such as nonalcoholic steatohepatitis. The company was founded by Bronislava Gedulin and Michael G. Grey in January 2011 and was headquartered in San Diego, CA. | Health Technology |
NDA Partners LLC
 NDA Partners LLC Miscellaneous Commercial ServicesCommercial Services NDA Partners LLC provides strategy consulting services. It also provides a comprehensive range of services across the product development life cycle for drugs, biologics, biosimilars, vaccines, generics, devices, combination products and diagnostics. The company was founded by Carl C. Peck and Earle Martin and is headquartered in Annapolis, MD. | Commercial Services |
Warner-Lambert Co.
 Warner-Lambert Co. Pharmaceuticals: MajorHealth Technology Warner-Lambert Co. used to manufacture and market pharmaceuticals, consumer health care products & confectionery. Its pharmaceutical products were ethical pharmaceuticals, biological products and hard-gelatin capsules. Its consumer health products were a wide range of products like oral care mouthwash/dental rinses, toothpaste, effervescent denture cleaning tablets, upper respiratory cold & sinus preparations, antihistamines, allergy products and cough syrups/suppressants. The company was headquartered in Morris Plains, NJ. | Health Technology |
Boehringer Ingelheim GmbH
 Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Health Technology |
Pappas Capital LLC
Pappas Capital LLC Investment ManagersFinance Pappas Capital LLC (Pappas Ventures) is a venture capital firm founded in 1994 by Art M. Pappas. The firm is headquartered in Durham, North Carolina. | Finance |
